Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + paclitaxel + Reolysin
- Development stage
- Phase 3
- Lead developer
- Oncolytics Biotech
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of two chemotherapy agents (carboplatin and paclitaxel) plus an oncolytic virus (Reolysin/pelareorep). Carboplatin is a platinum-based chemotherapy that works by crosslinking DNA, interfering with cell division. Paclitaxel is a taxane that stabilizes microtubules, preventing cell division. Reolysin is a formulation of wild-type reovirus that selectively replicates in and kills cancer cells with activated Ras pathways. The combination leverages multiple mechanisms to target cancer cells, including DNA damage, mitotic arrest, and virus-mediated cell death. Reolysin also demonstrates anti-angiogenic properties through induction of CXCL10.
- Other names
- carboplatin + paclitaxel + pelareorepCarbo-Taxol + Reolysin
02
Targets
DNAJAM-A (Junctional adhesion molecule A)MicrotubuleSialoglycan (Cell-surface sialoglycan)CXCL10 (C-X-C Motif Chemokine Ligand 10)MAPK3 (Mitogen-activated protein kinase 1)
Beyond the preview
Go deeper on carboplatin + paclitaxel + Reolysin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + paclitaxel + Reolysin.